Background: Infection with dengue virus (DENV) may cause life-threatening disease with thrombocytopenia and vascular leakage which are related to dysfunction of platelets and endothelial cells. We previously showed that antibodies (Abs) against DENV nonstructural protein 1 (NS1) cross-react with human platelets and endothelial cells, leading to functional disturbances. Based on sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes. For safety in vaccine development, the cross-reactive epitopes of DENV NS1 protein should be deleted or modified.
Introduction
Dengue virus (DENV) belongs to the Flaviviridae family of enveloped, positive-strand RNA viruses, and is transmitted by Aedes mosquitoes. With increased international travel and climate change, the prevalence of dengue is spreading beyond its usual tropical and subtropical boundaries. Hence, dengue is becoming one of the most important health issues in the world. DENV infection causes variable clinical presentations ranging from mild dengue fever to severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of DHF/DSS are thrombocytopenia and vascular leakage, although additional symptoms, such as liver damage, may occur [1] [2] [3] [4] .
So far, there is no vaccine or specific antiviral drug available. One of the obstacles is the lack of suitable animal models for human dengue disease. DENV can infect nonhuman primates but does not replicate well or cause substantial disease. For reasons of cost and convenience, mouse models have been used to test vaccine candidates prior to testing in nonhuman primates. Recent progress has been made in modeling certain aspects of human dengue disease in mice. Following intravenous, intraperitoneal, intracerebal or intradermal inoculation of DENV, mice show liver pathology, thrombocytopenia, neurological symptoms, or hemorrhage [5] . A dengue hemorrhage mouse model has been established which mimics the natural route of infection in humans. This model gives rise to severe thrombocytopenia, prolonged bleeding time, and increased numbers of circulating endothelial cells. TNF-a produced by monocytes and infiltrating macrophages enhances production of DENV-induced reactive nitrogen species and reactive oxygen species and also leads to endothelial cell damage [6] [7] [8] . Hence, the murine model can be used to test for many parameters of vaccine efficacy including hemorrhage which is a common clinical manifestation seen in DHF/DSS patients.
For dengue vaccine development, the envelope (E) and precursor membrane (prM) proteins are major antigens for inducing protective antibody (Ab) responses. However, Abs against E and prM are not only neutralizing but also enhancing which facilitate DENV infection through Ab-dependent enhancement (ADE) [9] [10] [11] [12] [13] [14] [15] . On the other hand, nonstructural protein 1 (NS1) is also an important target of Abs induced by DENV and is a candidate for vaccine development. As a nonstructural protein, NS1 can avoid the risk of ADE. Importantly, anti-NS1 Abs trigger complement-mediated lysis of DENV-infected cells [16] . Furthermore, several studies showed that active immunization with NS1 protein or NS1 DNA vaccine, as well as passive immunization with anti-NS1 Abs provided protection for mice from DENV challenge [16] [17] [18] [19] [20] . A downside to the use of NS1 as a vaccine, however, is that anti-NS1 Abs may cross-react with human coagulation factors, adhesion molecules or LYRIC (lysine-rich CEACAM1 co-isolated) on platelets, and endothelial cells [21] [22] [23] [24] .
We previously showed that anti-DENV NS1 Abs cross-react with platelets and inhibit platelet aggregation [25] . In addition, anti-DENV NS1 Abs can bind to endothelial cells and cause cell apoptosis or inflammatory activation [26, 27] . Based on proteomic and sequence homology analysis, the C-terminal region of DENV NS1 protein contains cross-reactive epitopes shared with several self-antigens [28] . Therefore, we deleted the C-terminus of DENV NS1 proteins from amino acids (a.a.) 271-352 to generate DC NS1 proteins. Anti-DC NS1 Abs showed a lower binding activity to human platelets and did not inhibit platelet aggregation. Moreover, DENV NS1, but not DC NS1, immunization caused prolonged bleeding time in mice [29] . In the present study, we tested the protection provided by Abs against modified NS1 proteins against DENV challenge. Besides DC NS1 protein, we generated a chimeric DJ NS1 protein, which consisted of Nterminal DENV NS1 (a.a. 1-270) and C-terminal Japanese encephalitis virus (JEV) NS1 (a.a. 271-352). The Abs against full-length DENV NS1, DC NS1 and DJ NS1 proteins were assayed for their pathogenic or protective effects both in vitro and in vivo.
Materials and Methods

Mice
C3H/HeN breeder mice were obtained from Charles River Breeding Laboratories. They were maintained on standard laboratory food and water in our medical college laboratory animal center. Their 8-week-old progeny were used for the generation of Abs and their 4-5-week-old progeny were used for protection studies. Housing, breeding, and experimental use of the animals were performed in strict accordance with the Experimental Animal Committee of National Cheng Kung University.
Preparation of recombinant proteins and Abs
The cDNA of DENV2 NS1 (New Guinea C strain) was cloned into the pRSETb vector containing a His-tag. DC NS1 (deletion of a.a. 271-352) and DJ NS1 (a.a. 1-270 of DENV NS1 and a.a. 271-352 of JEV NS1) cDNA were cloned into the pET28a vector also containing a His-tag. The plasmids were introduced into E. coli BL21. The recombinant proteins were induced by 1 M isopropyl B-D-1-thiogalgactopyranoside (IPTG) (Calbiochem) and purified with Ni 2+ columns. After purification, proteins were examined using 10% SDS-PAGE. Proteins from SDS-PAGE were excised and homogenized in Freund's adjuvant (Sigma-Aldrich) to intraperitoneally (i.p.) immunize mice five times at a dose of 25 mg. The first dose was administered in complete Freund's adjuvant (CFA) and the following four doses were given in incomplete Freund's adjuvant (IFA). Mouse sera were collected three days after the last immunization. The polyclonal Abs against DENV NS1, DC NS1 and DJ NS1 from hyperimmunized sera were purified with protein G agarose columns (Millipore) and recovered with HCl-glycine. The control IgG was eluted from a protein G column loaded with normal mouse sera. The preparations were subjected to testing for endotoxin contamination using a Limulus amebocyte lysate assay (Pyrotell, Associates of Cape Cod), the endotoxin concentrations of anti-DENV NS1, anti-DC NS1, anti-DJ NS1 and control IgG were all ,0.03 EU/ ml.
Bleeding time
Bleeding time was performed by a 3-mm tail-tip transection. Blood droplets were collected on filter paper every 30 sec. Bleeding time was recorded when the blood spot was smaller than 0.1 mm in diameter [29, 30] .
Cell and virus cultures
Human microvascular endothelial cell line-1 (HMEC-1) was obtained from the Centers for Disease Control and Prevention (Atlanta) [31] , and passaged in culture plates using endothelial cell growth medium M200 (Cascade Biologics) containing 2% FBS, 1 mg/ml hydrocortisone, 10 ng/ml epidermal growth factor, 3 ng/ml basic fibroblast growth factor, 10 mg/ml heparin, and antibiotics.
DENV2 (strain 16681) was propagated in C6/36 cells. Briefly, C6/36 monolayers were incubated with DENV at multiplicity of infection (MOI) of 0.01 at 28uC in 5% CO 2 for 5 days. The cultured medium was harvested, and cell debris was removed by centrifugation at 9006g for 10 min. After further centrifugation at 16,0006g for 10 min, the virus supernatant was collected and stored at 270uC until use in experiments. Virus titer was determined by plaque assay using BHK-21 cells as described previously [32] .
Platelet preparation
Human whole blood (collected by the ethical approval from the Institutional Review Board of National Cheng Kung University Hospital, No. A-ER-102-123, with written informed consent obtained from healthy volunteers) containing the anticoagulant ACD (29.9 mM sodium citrate, 113.8 mM glucose, 72.6 mM sodium chloride and 2.9 mM citric acid, pH 6.4) was centrifuged at 10006g for 10 min at room temperature. The upper layer as platelet-rich plasma was removed to a 15-ml tube and washed twice in EDTA/PBS. The washed platelets were suspended in Tyrode's solution (137 mM NaCl, 20 mM HEPES, 3.3 mM NaH 2 PO 4 , 2.7 mM KCl, 1 mg/ml BSA and 5.6 mM glucose, pH 7.4) at a concentration of 10 8 platelets/ml [29] .
Flow cytometry
For platelet and endothelial cell binding assay, the washed platelets and endothelial cells were fixed with 1% formaldehyde at room temperature for 10 min and then washed with PBS. Control IgG, anti-DENV NS1, anti-DC NS1 and anti-DJ NS1 Abs were incubated with platelets or endothelial cells at 4uC for 1 h. After washing twice with PBS, the samples were incubated with 1 ml of 1 mg/ml Alexa-488-conjugated goat anti-mouse IgG (Invitrogen) at 4uC for 30 min. The binding activity was analyzed by flow cytometry (FACSCalibur; BD Biosciences) with excitation set at 488 nm. The percentage of positive cells was determined by comparison with the control IgG group.
Animal protection model
Mice were injected i.p. with Abs (100 mg/mouse), followed one day later by intradermal (i.d.) inoculation with DENV (9610 7 pfu/mouse) at four sites on the upper back as previously described [6] . On days one and two post-infection, mice were further injected i.p. with Abs and were sacrificed at day 3 after inoculation.
Proteins from SDS-PAGE were excised and homogenized in Freund's adjuvant to i.p. immunize mice three times at a dose of 25 mg (once in CFA and then twice in IFA). Three days following the final immunization, mice were i.d. inoculated with DENV (9610 7 pfu/mouse) at four sites on the upper back and sacrificed at day 3 after inoculation. 
Histopathology
Mouse skin was fixed in 10% neutral-buffered formalin solution and then dehydrated in graded alcohol. The fixed tissue was embedded in paraffin and sliced into 4-mm-thick sections. The skin sections were mounted in regular glass slides and stained with hematoxylin and eosin.
Immunohistochemistry staining
The skin sections were embedded in paraffin and sliced on slides. Using xylene and gradient alcohol (100%, 95%, 85%, 70% and 50%) to deparaffin, the sections incubated in 2N HCl solution for 20 min and then with 20 mg/ml proteinase K in TE buffer (50 mM Tris Base, 1 mM EDTA, 0.5% Triton X-100, pH 8.0) for another 20 min at room temperature. The sections were incubated with 3% H 2 O 2 in water for 15 min to inhibit endogenous peroxidase activity and blocked by 10% BSA in PBS.
The primary and secondary Abs were adequately diluted in Ab diluents (Dako Corporation). Cells containing DENV antigen were detected with anti-DENV NS3 Abs (GeneTex) overnight at 4uC, followed by HRP conjugated goat anti-rabbit Abs at room temperature for 1 h (Jackson Immunoresearch Laboratories). The infiltrating macrophages were stained with anti-mouse F4/ 80 Abs (Serotec) overnight at 4uC, followed by biotin-labeled donkey anti-rat Abs (Jackson Immunoresearch Laboratories) at room temperature for 2 h. After washing with PBS, the sections were incubated with streptavidin (Dako Corporation) at room temperature for 15 min. The skin sections were developed using the AEC substrate kit (Vector Laboratories) and counterstained with hematoxylin. The sections were also analyzed using a TissueFAXS (TissueGnostics Vienna, Austria) image cytometer and quantified with the HistoQuest software (TissueGnostics) using an average of 15 fields of view. HistoQuest separated the Abmediated chromogen (AEC) stain and the counterstain. Results were displayed as dot plots with each dot representing a single cell in the tissue sample.
Immunofluorescence staining
The skin tissues were frozen in liquid nitrogen and the cryosections were fixed in 4% formaldehyde for 3 min and acetone for 5 min at room temperature. The sections were then blocked with 10% BSA in PBS for 30 min at room temperature. Sections were stained with anti-NS3 and anti-CD31 Abs (BD Biosciences) in Ab diluents overnight at 4uC, followed by Alexa-488-conjugated donkey anti-rabbit Abs (Invitrogen) and Alexa-594-conjugated donkey anti-rat Abs (Invitrogen) at room temperature for 2 h. The nuclei of cells were stained with DAPI (Calbiochem). Fluorescence images were detected using an Olympus BX-51 microscope.
Ab-dependent complement-mediated cytolytic assay
HMEC-1 cells were inoculated with DENV (MOI = 10) for 1 h at 37uC and then washed twice with medium. After centrifugation to remove residual virus in the culture supernatant, 5610 3 cells were seeded into each well of 96-well tissue-culture plates for further incubation in 5% CO 2 in a 37uC incubator. At 72 h postinfection, DENV-infected HMEC-1 cells (about 45% E antigenpositive) were harvested and incubated with Abs (50 mg/ml) at 4uC for 1 h. After washing twice with PBS, cells were incubated with Low-Tox-M rabbit complement (1:20 dilution, Cedarlane Laboratories Ltd) for 4 h in 5% CO 2 in a 37uC incubator to facilitate complement-mediated cell lysis. Cytolysis was measured by the release of lactate dehydrogenase (LDH), a cytoplasmic enzyme, with a commercial kit (Cytotoxicity detection kit, Roche Diagnostics). The optimal density was determined using a microplate reader set to 490 nm.
Effect of Abs and complement on DENV replication
To measure the effect of Abs and complement on virus production in vitro, HMEC-1 cells in 96-well plates were infected with DENV at an MOI of 10 for 1 h. Residual extracellular virus was then removed by washing three times with medium. After 6 h incubation, the medium was then replaced with medium containing Abs (50 mg/ml) and complement (1:20) . Cells were incubated for 72 h at 37uC in a 5% CO 2 incubator. At 24 h intervals, culture supernatants were collected for determination of infectious virus titer by plaque assay. 
Statistics
Comparisons between various treatments were performed by unpaired t-test with GraphPad Prism version 5.0. Statistical significance was set at P,0.05.
Results
Absence of pathogenic effects of Abs against modified NS1 proteins lacking cross-reactive epitopes both in vitro and in vivo
We previously found that anti-DENV NS1 Abs cross-react with platelets and endothelial cells [25, 26] and the cross-reactive epitopes are located predominantly in the C-terminal region of the DENV NS1 protein [28, 33] . We therefore deleted the C-terminus of DENV NS1 protein from a.a. 271-352 to generate DC NS1 protein. We also generated a chimeric DJ NS1 protein, which consists of N-terminal DENV NS1 (a.a. 1-270) and C-terminal JEV NS1 (a.a. 271-352) ( Figure 1A ). The Abs against DENV NS1, DC NS1 or DJ NS1 proteins were purified from sera of immunized mice and tested for binding activity to human endothelial cells and platelets. Our previous study showed that the binding ability of anti-DC NS1 to platelets was lower than that of anti-full-length NS1 Abs [29] . Here, we further showed that the binding activity of anti-DC NS1 and anti-DJ NS1 Abs to human endothelial cells ( Figure 1B ) and to platelets ( Figure 1C) were lower than that of anti-DENV NS1 Abs. Therefore, the cross-reactivity of anti- DENV NS1 Abs was reduced after the above-described modifications of the NS1 C-terminus. In this study, we also compared the bleeding times of mice immunized with DENV NS1, DC NS1, DJ NS1 or JEV NS1 proteins. The results showed that immunization with unmodified DENV NS1 caused prolonged bleeding time in mice, but immunization with DC NS1 and DJ NS1 did not. JEV NS1-immunized mice and normal mice were negative controls ( Figure 2 ). These results suggest that full-length DENV NS1 and its Abs show pathogenic effects but not different versions of Cterminal modified NS1 and their Abs.
Protective effects of Abs against modified NS1 proteins in a DENV-induced hemorrhagic mouse model A mouse model of DENV-induced hemorrhage using intradermal inoculation of virus was previously established [6] [7] [8] . The hemorrhagic mice showed manifestations of severe thrombocytopenia, prolonged bleeding time, and increased numbers of circulating endothelial cells and infiltrating macrophages. To test the protective effects provided by various Abs, DENV-challenged mice were passively administered with anti-DENV NS1, anti-DC NS1 or anti-DJ NS1 Abs. Results showed that while mice infected with DENV alone or passively immunized with normal control IgG showed prolonged bleeding time, passive immunization with anti-DC NS1 or anti-DJ NS1 Abs reduced the bleeding time ( Figure 3 ). Passive immunization with anti-full-length DENV NS1 Abs did not cause a significant reduction of bleeding time as compared with the control group. A recent report demonstrated that Abs from dengue patient sera bind to thrombin and inhibit its activity, thereby possibly contributing to the development of hemorrhage in patients with DHF [34] . Therefore, we determined the thrombin activity in our DENV-induced hemorrhagic mouse model. Results showed that the thrombin activity in mice treated with DENV plus control IgG was significantly reduced comparing with the uninfected mice. DENV-infected mice treated with anti-DC NS1 and anti-DJ NS1 Abs, but not with anti-DENV NS1 Abs, could partially rescue the inhibition of thrombin activity ( Figure  S1 ). These data indicate that anti-DC NS1 or anti-DJ NS1 Abs reduce DENV-induced prolonged bleeding time and reverse DENV-reduced thrombin activity. However, anti-full-length DENV NS1 Abs did not reduce or reverse these effects.
Next, we observed hemorrhage development in the mouse skin tissues. Results showed that anti-DENV NS1 (Figure 4d ), anti-DC NS1 (Figure 4e ) and anti-DJ NS1 (Figure 4f ) Abs reduced DENVinduced hemorrhage in the skin as compared with mice inoculated with DENV alone (Figure 4b ) or mice treated with control IgG (Figure 4c ). Mice inoculated with culture medium were used as negative control (Figure 4a ). Histopathological examination of the skin sections showed that mice inoculated with DENV alone (Figure 4h ) or with control IgG (Figure 4i ) displayed red blood cell extravasation, which was not observed in mice treated with anti-DENV NS1 (Figure 4j ), anti-DC NS1 (Figure 4k ) or anti-DJ NS1 (Figure 4l ). Mice inoculated with culture medium were used as the negative control to show that simple intradermal injections did not lead to hemorrhage development (Figure 4a, g ). These data demonstrate that anti-DENV NS1, anti-DC NS1 or anti-DJ NS1 Abs reduce DENV-induced hemorrhage.
We next checked the presence of DENV NS3, a marker for viral replication, in the mouse skin sections. Immunohistochemical staining showed that cells in the dermis layer ( Figure 5A , b) expressed NS3 in mice treated with DENV plus control IgG. However, anti-DENV NS1 ( Figure 5A, c) , anti-DC NS1 ( Figure 5A, d ) and anti-DJ NS1 ( Figure 5A , e) Abs reduced DENV antigens in the skin tissues. Mice inoculated with culture medium were used as the negative control ( Figure 5A, a) . The images of immunohistochemical staining were further quantified. Results of HistoQuest analysis show that DENV-infected mice treated with anti-DC NS1 and anti-DJ NS1 Abs as well as anti-DENV NS1 Abs significantly reduced the levels of viral NS3 in infected mice ( Figure 5B ). Immunofluorescence staining also showed that CD31
+ vascular endothelial cells in the skin sections expressed NS3 in mice treated with DENV plus control IgG. In contrast, DENV-infected mice treated with anti-DC NS1 and anti-DJ NS1 Abs as well as anti-DENV NS1 Abs reduced the levels of viral NS3 in CD31 + endothelial cells ( Figure 5C ).
Abs against modified NS1 proteins induce complementmediated cytotoxicity in DENV-infected endothelial cells and inhibit viral replication
Several studies suggested that flavivirus NS1-specific Abs kill infected cells in a complement-dependent manner [35] [36] [37] [38] . In DENV infection, complement activation is triggered by Abs binding to the NS1 proteins expressed on the surface of infected cells [16, 18] . We confirmed the enhanced binding ability of anti-DENV NS1, DC NS1 and DJ NS1 Abs to DENV-infected endothelial cells. These results indicate that these Abs can bind the NS1 protein expressed on the cell surface by DENV infection ( Figure S2 ). To determine whether these Abs can cause cytolysis of DENV-infected cells in the presence of complement, a complement-mediated cytotoxicity assay was performed. Compared to control IgG treatment, treatment with anti-DC NS1, anti-DJ NS1 and anti-DENV NS1 Abs, had the ability to lyse DENV-infected cells in the presence of complement as measured by the release of LDH ( Figure 6A) . A previous study demonstrated that anti-JEV NS1 Abs caused a complement-dependent reduction in virus output from infected human cells, indicating an important role in viral control [37] . To test the effect of Abs and complement on DENV replication, DENV-infected endothelial cells were treated with anti-DENV NS1, anti-DC NS1 or anti-DJ NS1 Abs plus complement. Virus in the culture medium at the indicated time points was measured by plaque assay. At 72 h post-infection, there was a significant reduction in virus titer observed in the presence of anti-DC NS1 and anti-DJ NS1 Abs, as compared to control IgG plus complement or complement alone ( Figure 6B ). These results indicate that anti-DC NS1 and anti-DJ NS1 Abs induce complement-mediated cytolysis of cells which express NS1 proteins on their surface and are consequently unable to support viral replication. Abs against modified NS1 proteins reduce macrophage infiltration in DENV-induced hemorrhagic mouse model Endothelial cell damage or activation is accompanied by infiltrating macrophages and circulating monocytes that secrete TNF-a [7, 39] . In this study, immunohistochemistry staining showed that mice inoculated with DENV plus control IgG revealed close contact of F4/80-positive macrophages to endothelium ( Figure 7A, b) . In addition, F4/80-positive macrophages were also observed infiltrating to the dermis layer ( Figure 7A, g ). In contrast, there were no or only few infiltrating macrophages in the endothelium layer ( Figure 7A , c-e) and the dermis ( Figure 7A , h-j) in mice treated with anti-DENV NS1, anti-DC NS1 or anti-DJ NS1 Abs. Mice inoculated with culture medium were used as the negative control showing no or only few infiltrating macrophages close to the endothelium and in the dermis layer ( Figure 7A, a, f) . The images of immunohistochemical staining were further quantified using HistoQuest analysis software. Treatment with anti-DC NS1 and anti-DJ NS1 Abs as well as anti-DENV NS1 Abs showed significant reduction of infiltrating macrophages ( Figure 7B ). These results suggest that anti-DENV NS1, anti-DC NS1 or anti-DJ NS1 Abs reduce DENV-induced inflammation by inhibiting macrophage infiltration.
Active immunization with modified NS1 provides protection in the DENV-induced hemorrhagic mouse model
To further test the protective efficacy of modified NS1 proteins, we used active immunization protocols in the mouse model. Mice were actively immunized with DENV NS1 or DJ NS1 proteins before DENV challenge. The results showed that active immunization with DJ NS1 significantly reduced the DENV-induced prolonged bleeding time to a level similar to the uninfected group. However, active immunization with DENV NS1 did not reduce the DENV-induced prolonged bleeding time ( Figure 8) .
Next, we observed both hemorrhage development and DENV NS3 levels in the mouse skin tissues. Results showed that DENV NS1 ( Figure 9A, c) and DJ NS1 (Figure 9A, d) immunization reduced DENV-induced hemorrhage in the skin as compared with mice inoculated with DENV alone (Figure 9A, b) . Mice inoculated with culture medium were used as negative control ( Figure 9A, a) . Histopathological examination of the skin sections showed that mice inoculated with DENV alone (Figure 9A , f) displayed red blood cell extravasation, which was not observed in mice immunized with DENV NS1 (Figure 9A, g ) or DJ NS1 ( Figure 9A, h ) before DENV challenge. Mice inoculated with culture medium were used as a negative control to show that intradermal injection itself did not lead to hemorrhage development ( Figure 9A, e) . Immunohistochemical staining showed that cells in the dermis layer expressed NS3 in mice inoculated with DENV ( Figure 9B, b) . Active immunization with DJ NS1 protein significantly reduced DENV NS3 antigen expression in the skin tissues ( Figure 9B, d) , whereas active immunization with DENV NS1 protein showed less reduction of the levels of viral NS3 in infected mice ( Figure 9B, c) . Mice inoculated with culture medium were used as a negative control (Figure 9B, a) . The images of immunohistochemical staining were further quantified by HistoQuest analysis ( Figure 9C ). Taken together, these results indicate that DJ NS1 exhibits lower pathogenic effects and is a better candidate than unmodified DENV NS1 for future dengue vaccine development.
Discussion
This is the first study demonstrating vaccine potential for Abs against a modified DENV NS1 protein, from which harmful crossreactive epitopes have been selectively deleted. Although the NS1 protein is not a virion structural protein, Abs against it can protect against infection of several flaviviruses in vivo, such as Yellow Fever Virus [35, 40] , JEV [36, 41] , West Nile Virus [42, 43] and DENV [16, [18] [19] [20] 44] . Abs against NS1 exhibit cytolytic activity to kill virus-infected cells in a complement-dependent manner. In the present study, we demonstrate that not only anti-DENV NS1 Abs but also anti-DC NS1 and anti-DJ NS1 Abs possess the ability of Ab-mediated complement-dependent cytotoxicity. Moreover, all three Abs have the ability to control viral load in vivo ( Figure 5 ) and in vitro ( Figure 6B) . A previous report showed that anti-NS1 Abs trigger Fcc receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells [45] . Therefore, in addition to Abmediated complement-dependent cytotoxicity, other mechanisms by which anti-DC NS1 and anti-DJ NS1 Abs contribute to protection from DENV challenge need to be further investigated.
Anti-full-length NS1 exhibited higher endothelial cell or platelet binding activity than that of anti-DC NS1 and anti-DJ NS1 Abs ( Figure 1B and C) . In addition, anti-DENV NS1 Abs, in the presence of complement, cause cytolysis of uninfected endothelial cells due to cross-reactive effects ( Figure S3 ). These results suggest that full-length DENV NS1 and its Abs show undesirable pathogenic effects but not the various forms of C-terminal modified NS1 and their Abs. Although all three Abs show similar protective effects at local infection sites or in DENV-infected cell culture (Figure 4, 5, 6, 7) , the DENV-induced prolonged bleeding time was markedly reduced when mice were treated with anti-DC NS1 and anti-DJ NS1 Abs whereas the reduction in bleeding time mediated by anti-full-length DENV NS1 Abs was not statistically significant ( Figure 3) . Furthermore, active immunization with DJ NS1, but not DENV NS1, significantly reduced the DENVinduced prolonged bleeding time (Figure 8 ), hemorrhage development, and DENV NS3 antigen levels ( Figure 9) . Therefore, the various forms of C-terminal modified NS1 and their Abs provide better protection against virus challenge than full-length DENV NS1 and its Abs by reducing the risk of pathogenic effects. Although anti-DC NS1 and anti-DJ NS1 Abs show similar protective effects, further studies are necessary to discriminate possible differences in protein conformation and antigenicity.
Previous studies in our laboratory identified major cross-reactive epitopes in the C-terminus (a.a. 271-352) of DENV NS1 [28, 29, 33, 46] . Recent studies also indicated that a.a. 116-119 of DENV NS1 share similar sequences with human LYRIC (a.a. 334-337) [23] . Also, Abs generated to ELK/KLE-type motifs in the NS1 reacted with blood blotting and adhesion molecules [21, 22] . Therefore, these and possibly other epitopes should be further characterized to decrease the risk of cross-reactivity from a vaccine safety perspective.
So far no licensed dengue vaccines are available, but there are some successful vaccines for other flaviviruses such as Yellow Fever Virus or JEV [47] . One of the reasons is that, unlike other monotypic flaviviruses, there are four serotypes of DENV. Even worse, anti-DENV Abs, especially anti-E or anti-prM Abs, not only do not provide cross-protection against other serotypes of DENV but also enhance the infection [12] [13] [14] . Therefore, many efforts have been directed at developing tetravalent vaccines against dengue [48] [49] [50] [51] [52] . One of the leading candidates, the Sanofi dengue vaccine, showed unequal efficacy against the four serotypes of DENV [53] . Much investigation is required to determine whether NS1 or modified NS1 proteins can provide protection against different serotypes.
An important aspect of our study is the use of dengue hemorrhage mouse model to evaluate the potential vaccine candidates. It was previously shown that NS1 immunization can prevent mortality caused by intracerebral inoculation of DENV [16, 18, 44] . The dengue hemorrhage mouse model we used in the present study mimicked the natural route of infection in humans. Infected mice developed hemorrhage and had prolonged bleeding time. Here we showed that passive immunization with Abs against DC NS1 and DJ NS1 were protective against DENV-induced hemorrhage. While recent reports demonstrated that Abs against DENV E protein [54, 55] and NS1 [56] represent new therapeutic candidates for treating DENV infection, our results show further that Abs against modified NS1 protein may provide additional therapeutic benefits by reducing potentially harmful cross-reactive effects.
In conclusion, we have shown in the present study the protective effects provided by Abs against DC NS1 and DJ NS1 proteins using a dengue hemorrhagic mouse model. Unlike anti-full-length DENV NS1 Abs, anti-DC NS1 and anti-DJ NS1 Abs do not crossreact with uninfected endothelial cells and platelets, and do not cause prolonged bleeding time in mice. Our findings suggest that C-terminal modification of NS1 proteins may be an attractive strategy for dengue vaccine development.
Supporting Information
Figure S1 Anti-DC NS1 and anti-DJ NS1 Abs rescue DENV-induced thrombin activity inhibition. Thrombin activity was detected by adding chromogenic substrates S-2238 to the mouse plasma and incubating at room temperature for 1 h. The optical density value at 405 nm was measured every 10 min with a VersaMax microplate reader [34] . The inhibition of thrombin activity occurred in the DENV plus control IgG group compared to medium control and was partially rescued by anti-DC NS1 and anti-DJ NS1 Abs treatment (n = 4/group). * P,0.05. 
